Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase ...

Implementing LGBTQ+ inclusive language in patient care and clinical trials for dermatology could improve data accuracy, ...

Science-backed pampering with radiant results? Yes, please! These are some of the best spa treatments available throughout ...

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...

Zinc is an essential nutrient with many health benefits. Learn about zinc's health benefits, food sources, safety concerns, ...

In light of the promising results, Ascletis is planning to seek approval for denifanstat from the China National Medical Products Administration. Moreover, Sagimet has initiated a Phase 1 clinical ...

Sagimet Biosciences (NASDAQ:SGMT) added ~38% in the premarket on Wednesday after the company said its Chinese licensing ...

Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne. The stock jumped 42%, to $5.20 ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

Is red light therapy the holy grail of holistic health remedies, or is it a scam? I took a deep dive to discover the benefits ...